Plasma Proteome-Driven Liquid Biopsy for Individualized Monitoring and Risk Stratification of Immune-Related Adverse Events in Checkpoint Immunotherapy.

ABSTRACT: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, however, their use is limited by heterogeneous and unpredictable immune-related adverse events (irAEs), which can progress to life-threatening conditions requiring intensive care unit (ICU) admission. Reliable biomarkers for predicting and stratifying ICU-level irAEs are urgently needed to improve immunotherapy safety and critical care management. Here, we performed comprehensive mass spectrometry-based proteomic profiling to identify plasma biomarkers for the prediction and monitoring of irAEs in 65 patients receiving ICI treatment. Our analysis identified 217 differentially abundant proteins and four co-expression modules related to humoral (antibody-mediated) and cellular (T cell-mediated) immunity spanning mild to

SUBMITTER: Yan D 

PROVIDER: S-EPMC12818211 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature